Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Background & Aims The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530
(NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment …

Hepatitis C virus (HCV) infection is a major cause of severe liver disease including chronic
hepatitis, cirrhosis and hepatocellular carcinoma. The HCV burden in public health is …

Virus sequence data are an essential resource for reconstructing spatiotemporal dynamics
of viral spread as well as to inform treatment and prevention strategies. However, the …

This review is a Part II of the series aiming to provide comprehensive overview of currently
used antiviral drugs and to show modern approaches to their analysis. While in the Part I …

New SARS-CoV-2 mutants have been continuously indentified with enhanced transmission
ever since its outbreak in early 2020. As an RNA virus, SARS-CoV-2 has a high mutation …

Hepatitis C virus (HCV) core is a highly conserved and multifunctional protein that forms the
viral capsid, making it an attractive target for HCV detection and inhibition. Aptamers are in …

Abstract On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …

The introduction of highly potent direct‐acting antivirals (DAAs) has revolutionized hepatitis
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …